Kilitch Drugs (India) Ltd

KILITCH
Health CarePharmaceuticals
SmallcapWith a market cap of ₹244 cr, stock is ranked 1,612
High RiskStock is 3.07x as volatile as Nifty
151.755.50 (-3.50%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹244 cr, stock is ranked 1,612
High RiskStock is 3.07x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
65.08
PB RatioPB Ratio
1.88
Dividend YieldDiv. Yield
Sector PESector PE
32.03
Sector PBSector PB
4.78
Sector Div YldSctr Div Yld
0.86%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Kilitch Drugs (India) Limited is engaged in the development and operations of pharmaceutical business. The Company's services range from manufacturing to marketing a host of formulations in solid, liquid and parenteral forms.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201820192020202153.8986.4957.4571.195.153.820.833.75
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

General updates 
Announced OnMay 19, 2022

Kilitch Drugs (India) Limited has informed the Exchange about Submission of Acknowledgement received from Securities and Exchange Board of India for the report submitted under regulation 10(7) of SEBI(Substantial Acquisition of Shares and Takeovers) Regulations, 2021 | Download

Kilitch Drugs (India) Limited has informed the Exchange about Submission of Acknowledgement received from Securities and Exchange Board of India for the report submitted under regulation 10(7) of SEBI(Substantial Acquisition of Shares and Takeovers) Regulations, 2021 | Download

Disclosure under SEBI Takeover Regulations 
Announced OnApr 27, 2022

Bhavin Mehta has submitted to the Exchange a copy of Disclosure under Regulation 10(6) of SEBI(Substantial Acquisition of Shares and Takeovers) Takeover Regulations , 2011 | Download

Bhavin Mehta has submitted to the Exchange a copy of Disclosure under Regulation 10(6) of SEBI(Substantial Acquisition of Shares and Takeovers) Takeover Regulations , 2011 | Download

Cash Dividend 
Ex. DateSep 20, 2019

Final • Div/Share: ₹ 0.5

See all events